跳至主要内容
临床试验/NCT01843855
NCT01843855已完成早期 1 期

The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass

Adrian Vella1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2011年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
已完成
发起方
Adrian Vella
入组人数
12
试验地点
1
主要终点
Change in Total Disposition Index from Study 1 (pre-RYGB) to Study 2 (post-RYGB)

研究概览

简要总结

The study is being undertaken to understand how a gastric bypass can affect a subject's diabetes even prior to their losing significant amounts of weight. The hypothesis of this study is that increased glucagon-like peptide-1 (GLP-1) secretion explains the amelioration in insulin secretion after Roux-en-Y Gastric Bypass (RYGB) surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Single (Participant)

入排标准

年龄范围
20 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects with type 2 diabetes mellitus or impaired fasting glucose concentration of > 110 mg/dL
  • Subjects registered to receive a Roux-en-Y Gastric Bypass (RYGB).

排除标准

  • Subjects taking thiazolidinediones
  • Subjects with active systemic illness
  • Subjects with active microvascular or macrovascular complications of their diabetes
  • For female subject: positive pregnancy test at the time of enrollment in study

研究组 & 干预措施

Exendin 9,39

Experimental

Subjects randomized to this arm will receive an infusion of exendin 9,39 of 300mmol/kg/min for 360 minutes.

干预措施: Exendin 9,39 (Drug)

Placebo

Placebo Comparator

Subjects randomized to this arm will receive a saline infusion for 360 minutes.

干预措施: Placebo (Drug)

结局指标

主要结局

Change in Total Disposition Index from Study 1 (pre-RYGB) to Study 2 (post-RYGB)

时间窗: baseline, 4 weeks post-operative intervention

The total disposition index equals the product of insulin secretion and insulin sensitivity.

次要结局

未报告次要终点

研究者

发起方
Adrian Vella
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Adrian Vella

Consultant, Endocrinology

Mayo Clinic

研究点 (1)

Loading locations...

相似试验